ICMR Set To Team Up With Domestic Manufacturers To Accelerate Indigenous Production Of Medical Devices & Diagnostic Products

Mumbai : In a bid to reduce India’s dependency on imports for its medical device needs, the Indian Council of Medical Research (ICMR) is set to join hands with domestic manufacturers to accelerate development of medical devices and diagnostic products and their scale-up, thus catalyzing their commercialization for public use.

The apex medical research body on February 21, 2022 invited Expression of Interest (EOI) from experienced Indian companies for collaboration in this regard. The last date for submitting EOI is March 15, 2022.

The Indian medical device market is currently valued at USD 11.2 billion and is experiencing a growth rate of 15 per cent CAGR and is poised to be USD 50 billion by 2025. India is dependent on imports for its medical device needs with about 80 per cent of medical devices being imported. In view of the huge import, dependency and long technology development cycle of medical devices, there is an urgent need for providing holistic support across the medical device development and commercialization cycle including R&D, scale-up, validation, regulatory compliance, market access etc.

To cater to the above challenges, ICMR has established Medical Device and Diagnostics Mission Secretariat (MDMS) at its headquarters with a vision to support and catalyze research, development and indigenous manufacturing of cost-effective medical devices to strengthen health care sector in India and reduce import dependency through a Mission mode consortia approach. MDMS will incentivize and motivate local manufacturing in India and provide holistic support to the technologies/ products nearing commercialisation.

The priority medical device and diagnostic products significantly contributing to imports were identified by ICMR under the PRoduct Ignition and Development Enabler (mPRiDE) program of MDMS.

Companies which have extensive experience and demonstrated capabilities in developing dialysis machines, ultrasonography, echocardiogram machines and extracorporeal membrane oxygenation (ECMO) machines are encouraged to put-up their application under this program. The medical device technologies at an advanced stage of development will be supported through this program. Subject to the terms and conditions of an agreement, ICMR-MDMS shall support indigenous development, scale-up and pilots of Make-in-India manufacturing of critical medical devices and diagnostic products.

Based on the recommendations of the Expert Committee the applications for manufacturing Make-In-India products in dialysis machines, ultrasonography, echocardiogram machine and extracorporeal membrane oxygenation (ECMO) machines categories will be duly considered for extending support.

The funding support under the present scheme is in the form of grant-in-aid. Extent of funding is up to Rs 1.5 crore based on merit.

  • Related Posts

    • Pharma
    • June 27, 2025
    • 60 views
    Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

    Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world’s first malaria vaccine for children ‘RTS,S’ developed by GSK, PATH and partners,…

    • Pharma
    • June 27, 2025
    • 72 views
    Sun Pharma ropes in Richard Ascroft as North America CEO

    Mumbai: Sun Pharma has announced the appointment of Richard Ascroft as the new North America (NAM) Chief Executive Officer (CEO). In a statement shared via LinkedIn, the company said, “We…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

    Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

    Sun Pharma ropes in Richard Ascroft as North America CEO

    Sun Pharma ropes in Richard Ascroft as North America CEO

    Torrent Pharma shares surge 4% as JPMorgan upgrades to overweight; 18% upside seen

    Torrent Pharma shares surge 4% as JPMorgan upgrades to overweight; 18% upside seen

    Most Advanced Cancer Care is New Chapter @ Sir Ganga Ram

    Most Advanced Cancer Care is New Chapter @ Sir Ganga Ram